During 2023, we have seen revisions to pharmaceutical legislation, countdown to Jan 2025 and the EU Joint Clinical Assessment, patient experience data on the rise, EU launch conditionality and many more changes/initiatives to help healthcare systems navigate the rise of breakthrough cell & gene therapy launches.
In 2024, gene therapy launches are expected to rise sharply across the world, with as many as 31 launches expected in the US alone.
How will HTA bodies react? Will healthcare systems be able to adapt quickly to the ever-increasing burden on budgets, especially with the high costs of gene therapies?
– Sophie Schmitz, Managing Partner, January 2024
Please enter your details in the form on the right to download the full whitepaper